Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 20/20 | 0.77 |
| ▸ | RAMP1 | O60894 | 10/20 | 0.69 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.62 |
| ▸ | CALCR | P30988 | 1/20 | 0.62 |
| ▸ | CALCA | P06881 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980309 | 1.00 | CALCRL (0.77) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL978961 | 1.00 | CALCRL (0.77) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL980311 | 1.00 | CALCRL (0.77) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL12921126 | 1.00 | CALCRL (0.77) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL12921128 | 0.99 | CALCRL (0.76) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL12948195 | 0.94 | CALCRL (0.68) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL12921129 | 0.93 | CALCRL (0.67) | CALCRLRAMP1RAMP3CALCRCALCA | |
| SCHEMBL6344530 | 0.92 | CALCRL (0.78) | CALCRLRAMP1RAMP3CALCR | |
| SCHEMBL6345602 | 0.92 | CALCRL (0.73) | CALCRLRAMP1RAMP3CALCR | |
| SCHEMBL979569 | 0.88 | CALCRL (0.63) | CALCRLRAMP1RAMP3CALCRCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765759-B2 | Monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2271346-B1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, CCKBR | CALCRL 2/4885RAMP1 169/4885RAMP3 105/4885 |
| US-20120121508-A1 | RADIOLABELED CGRP ANTAGONISTS | CALCRL, CALCR, GRPR | CALCRL 1/4885RAMP1 54/4885RAMP3 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.